Tag: Therapeutics
Phaxiam therapeutics (formerly erytech): Launch of a new preclinical program
Receive the value of the day for free every morning The data collected is essential for this processing and is intended for the relevant services of BFM Bourse and, where…
Phaxiam Therapeutics consolidated its shares – 09/18/2023 at 10:39
(AOF) – Phaxiam Therapeutics (formerly Erytech) announced today the completion of the consolidation of the shares making up its share capital as decided by the Chief Executive Officer on July…
Phaxiam Therapeutics has consolidated its shares
(AOF) – Phaxiam Therapeutics (formerly Erytech) announced today the completion of the consolidation of the shares making up its share capital as decided by the Chief Executive Officer on July…
Horizon Therapeutics: rise expected after the FTC drops ballast on the takeover by Amgen – 08/28/2023 at 14:39
(AOF) – Horizon Therapeutics is expected to rise more than 5% in pre-market on Wall Street after the US Federal Trade Commission (FTC) suspended its challenge to the acquisition of…
Lilly completes the acquisition of DICE Therapeutics – 08/10/2023 at 14:28
(AOF) – Eli Lilly and Company has completed the acquisition of DICE Therapeutics, Inc. This acquisition expands Lilly’s immunology portfolio to include DICE’s novel oral therapeutic candidates, including oral IL-17…
Eli Lilly: Acquisition of DICE Therapeutics Completed
(CercleFinance.com) – Eli Lilly announced today that it has completed the acquisition of DICE Therapeutics, allowing it to expand its immunology portfolio to include new oral therapeutic candidates from DICE,…
OSE Immunotherapeutics announces new public aid to support its innovation and research programs in the field of RNA Therapeutics – 08/01/2023 at 07:30
Nantes, France – August 1, 2023, 7:30 a.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces that the Company has received innovation aid of 200,000 euros from the French…
MaaT Pharma joins the Microbiome Therapeutics Innovation Group – 07/20/2023 at 18:23
MaaT Pharma (EURONEXT: MAAT – the “Company”), a late-stage biotechnology company, leader in the development of Microbiome Ecosystem TherapiesTM (MET) aimed at improving the survival of cancer patients, announces today…
Phaxiam Therapeutics (formerly Erytech): Akkadian Partners takes legal action – 07/04/2023 at 11:06
(AOF) – The activist fund Akkadian Partners, opposed to the merger between Erytech and Pherecydes (which gave birth to Phaxiam Therapeutics), indicates that it has kept all the shares it…
Eli Lilly: agreement to acquire Sigilon Therapeutics
(CercleFinance.com) – Eli Lilly announces a definitive agreement to acquire Sigilon Therapeutics, a biopharmaceutical company that seeks to develop functional remedies for patients with a wide range of acute and…
Erytech Pharma merges with Pherecydes and becomes Phaxiam Therapeutics – 06/26/2023 at 10:11
(AOF) – Erytech Pharma is up 1.23% to 0.82 euro after announcing that all the resolutions for which the Board of Directors recommended a favorable vote were adopted by its…
Bone therapeutics: Will present new data on ATO
Receive daily value for free every morning The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its service…